Last edition
News about "elisrasib "
D3 Bio Secures FDA IND Clearance for Two Oncology Programmes
The US FDA has cleared two Investigational New Drug (IND) applications from D3 Bio, paving the way for a phase I clinical trial of D3S-003 and a phase II combination study evaluating elisrasib (D3S-001) with D3S-002, marking a key step forward in the company’s oncology development pipeline.
Elisrasib | 23/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members